Peijia Medical Ltd. (DE:4WO)
FRANKFURT:4WO
4WO Stock Chart & Stats
€0.66
>-€0.01(-1.71%)
At close: 4:00 PM EST
€0.66
>-€0.01(-1.71%)
Day’s Range― - ―
52-Week Range€0.41 - €1.01
Previous CloseN/A
Volume0.00
Average Volume (3M)42.00
Market Cap
€302.68M
Enterprise Value€2.21B
Total Cash (Recent Filing)€610.52M
Total Debt (Recent Filing)€434.22M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding674,736,940
10 Day Avg. Volume128
30 Day Avg. Volume42
Financial Highlights & Ratios
PEG Ratio1.97
Price to Book (P/B)1.95
Price to Sales (P/S)5.04
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.15Price Target Upside74.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€97.43M
Bulls Say, Bears Say
Bulls Say
Gross Margins & Revenue GrowthSustained ~67% gross margin with multi-year revenue expansion signals durable product-level profitability and pricing power in implantable devices. High gross margins provide room to invest in R&D and sales capacity, improving the odds of converting scale into operating profits over months.
Manageable Leverage / CapitalizationLow debt-to-equity (~0.24) preserves financial flexibility and reduces refinancing risk while losses persist. This capitalization buffer supports ongoing clinical, regulatory, and commercial investment without immediate solvency pressure, a durable advantage during the multi-quarter path to break-even.
Improving Operating TrajectoryNarrowing losses and improved free cash flow versus prior years indicate operational progress and better cash conversion. If sustained, this trend reduces reliance on external funding and suggests management execution is improving, supporting a viable structural path to profitability over the next several quarters.
Bears Say
Persistent UnprofitabilityA ~-29% net margin in 2025 shows the business is not yet self-sustaining; persistent operating losses constrain reinvestment and force dependence on financing. Over months this undermines ability to scale commercial programs and can erode competitive position if profitability is not achieved.
Weak Cash Generation / Cash BurnMaterial negative operating cash flow and ~-325M free cash flow in 2025 create ongoing liquidity pressure and heighten reliance on external capital. Even with improvement versus 2023, sustained cash burn raises dilution or debt risk and limits strategic optionality in a capital-intensive medtech business.
Negative Returns On EquityROE of about -11% signals the company is destroying shareholder capital rather than generating returns. Persistently negative ROE reduces investor confidence and could impair future capital raising or partnerships, constraining growth investments and competitive positioning over the medium term.
Peijia Medical Ltd. News
4WO FAQ
What was Peijia Medical Ltd.’s price range in the past 12 months?
Peijia Medical Ltd. lowest stock price was €0.41 and its highest was €1.01 in the past 12 months.
What is Peijia Medical Ltd.’s market cap?
Peijia Medical Ltd.’s market cap is €302.68M.
When is Peijia Medical Ltd.’s upcoming earnings report date?
Peijia Medical Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 71 days.
How were Peijia Medical Ltd.’s earnings last quarter?
Peijia Medical Ltd. released its earnings results on Mar 25, 2026. The company reported -€0.024 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.024.
Is Peijia Medical Ltd. overvalued?
According to Wall Street analysts Peijia Medical Ltd.’s price is currently Undervalued.
Does Peijia Medical Ltd. pay dividends?
Peijia Medical Ltd. does not currently pay dividends.
What is Peijia Medical Ltd.’s EPS estimate?
Peijia Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Peijia Medical Ltd. have?
Peijia Medical Ltd. has 674,736,940 shares outstanding.
What happened to Peijia Medical Ltd.’s price movement after its last earnings report?
Peijia Medical Ltd. reported an EPS of -€0.024 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.586%.
Which hedge fund is a major shareholder of Peijia Medical Ltd.?
Currently, no hedge funds are holding shares in DE:4WO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peijia Medical Ltd.
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
4WO Stock 12 Month Forecast
Average Price Target
€1.15
▲(74.13% Upside)
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---